• News
  • BioTech

Orixegen's weight loss drug moving forward with FDA

San Diego-based Orexigen Therapeutics Inc. (Nasdaq: OREX) announced Tuesday that it has received word that the U.S. Food and Drug Administration considers the recent resubmission of its Contrave new drug application to be a complete response to the FDA's action letter from Jan. 31, 2011.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!